Boothbay Fund Management LLC Sells 49,090 Shares of Encompass Health Co. (NYSE:EHC)

Boothbay Fund Management LLC lowered its position in shares of Encompass Health Co. (NYSE:EHC) by 67.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 23,869 shares of the company’s stock after selling 49,090 shares during the quarter. Boothbay Fund Management LLC’s holdings in Encompass Health were worth $2,204,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Susquehanna Fundamental Investments LLC acquired a new position in Encompass Health during the fourth quarter valued at approximately $555,000. Coldstream Capital Management Inc. grew its holdings in Encompass Health by 3.2% during the fourth quarter. Coldstream Capital Management Inc. now owns 28,530 shares of the company’s stock valued at $2,635,000 after purchasing an additional 894 shares during the period. Oberweis Asset Management Inc. grew its holdings in Encompass Health by 11.2% during the fourth quarter. Oberweis Asset Management Inc. now owns 340,829 shares of the company’s stock valued at $31,476,000 after purchasing an additional 34,221 shares during the period. Hancock Whitney Corp boosted its holdings in shares of Encompass Health by 10.8% in the fourth quarter. Hancock Whitney Corp now owns 8,968 shares of the company’s stock valued at $828,000 after buying an additional 875 shares during the period. Finally, Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Encompass Health by 24.8% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 1,378,077 shares of the company’s stock valued at $127,265,000 after buying an additional 274,192 shares during the period. Institutional investors and hedge funds own 97.25% of the company’s stock.

Insider Activity at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the sale, the chief accounting officer now owns 69,164 shares in the company, valued at approximately $6,798,129.56. This represents a 6.79 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 2.10% of the stock is owned by company insiders.

Encompass Health Trading Up 11.8 %

Shares of Encompass Health stock opened at $113.33 on Monday. Encompass Health Co. has a 12-month low of $82.38 and a 12-month high of $114.38. The stock has a market cap of $11.41 billion, a P/E ratio of 25.41, a P/E/G ratio of 2.31 and a beta of 0.87. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. The business’s 50 day moving average is $100.08 and its 200-day moving average is $98.57.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. Equities research analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st were paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend was Tuesday, April 1st. Encompass Health’s dividend payout ratio is currently 15.25%.

Wall Street Analysts Forecast Growth

EHC has been the subject of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $110.00 price target on shares of Encompass Health in a report on Tuesday, February 11th. KeyCorp upped their price target on shares of Encompass Health from $120.00 to $122.00 and gave the company an “overweight” rating in a report on Friday. Barclays upped their price target on shares of Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a report on Friday. StockNews.com upgraded shares of Encompass Health from a “hold” rating to a “buy” rating in a report on Friday. Finally, William Blair reiterated an “outperform” rating on shares of Encompass Health in a report on Friday, February 7th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $113.14.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.